Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.
Ulagamadesan VenkatesanKelley BranchLaura HeenanStephano Del PratoNardev S KhurmiCarolyn S P LamRichard PratleyJulio RosenstockNaveed SattarPublished in: Diabetes, obesity & metabolism (2020)
The results of the AMPLITUDE O trial will inform the use of exendin-based glucagon-like peptide-1 receptor agonist to people with T2DM and high CV risk, with and without CKD, in the presence and absence of an SGLT2 inhibitor.